References:
1. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al.
Treating childhood acute lymphoblastic leukemia without cranial
irradiation. N Engl J Med. 2009;360:2730–41.
2. Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bökkerink JP,
Bruin MC, et al. Dexamethasone-based therapy for childhood acute
lymphoblastic leukaemia: results of the prospective Dutch Childhood
Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncol.
2009;10:957–66.
3. Kamps WA, van der Pal-de Bruin KM, Veerman AJP, Fiocco M, Bierings M,
Pieters R. Long-term results of Dutch Childhood Oncology Group studies
for children with acute lymphoblastic leukemia from 1984 to 2004.
Leukemia. 2010;24:309–19.
4. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R,
Möricke A, et al. Molecular response to treatment redefines all
prognostic factors in children and adolescents with B-cell precursor
acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM
ALL 2000 study. Blood. 2010;115:3206–14.
5. Lehrnbecher T, Koehl U, Wittekindt B, Bochennek K, Tramsen L,
Klingebiel T, et al. Changes in host defence induced by malignancies and
antineoplastic treatment: implication for immunotherapeutic strategies.
Lancet Oncol. 2008;9:269–78.
6. Abdelmabood S, Fouda AE, Boujettif F, Mansour A. Treatment outcomes
of children with acute lymphoblastic leukemia in a middle-income
developing country: high mortalities, early relapses, and poor survival.
J Pediatr (Rio J). 2018;pii: S0021-7557(18)30583-7.
7. van Tilburg CM, Sanders EAM, Nibbelke EE, Pieters R, Revesz T,
Westers P, et al. Impact of reduced chemotherapy treatment for good risk
childhood acute lymphoblastic leukaemia on infectious morbidity. Br J
Haematol. 2011;152:433–40.
8. van Tilburg CM, Bierings MB, Berbers GAM, Wolfs TFW, Pieters R, Bloem
AC, et al. Impact of treatment reduction for childhood acute
lymphoblastic leukemia on serum immunoglobulins and antibodies against
vaccine-preventable diseases. Pediatr Blood Cancer. 2012;58:701–7.
9. Holmes EA, Friedman DL, Connelly JA, Dulek DE, Zhao Z, Esbenshade AJ.
Impact of IgG monitoring and IVIG supplementation on the frequency of
febrile illnesses in pediatric acute lymphoblastic leukemia patients
undergoing maintenance chemotherapy. J PediatrHematolOncol.
2019;41:423–8.
10. Kostaridou S, Polychronopoulou S, Psarra K, Kapsimali V, Kapsimali b
V, Katevas P, et al. Decrease of CD4 + and B-lymphocyte populations is
not associated with severe infectious complications in children with
acute lymphoblastic leukemia during maintenance. Int J Hematol.
2004;80:354–60.
11. Rapson NT, Cornbleet MA, Chessells JM, Bennett AJ, Hardisty RM.
Immunosuppression and serious infections in children with acute
lymphoblastic leukaemia: A comparison of three chemotherapy regimes. Br
J Haematol. 1980;45:41–52.
12. Luczyński W, Stasiak-Barmuta A, Krawczuk-Rybak M, Zak J. Immunologic
monitoring in children with acute lymphoblastic leukemia during
maintenance treatment with regard to co-existing infections. WiadLek.
2004;57:337–42.
13. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L,
Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell
transplantation: systematic review and meta-analysis. J ClinOncol.
2009;27:770–81.
14. Narula G, Khodaiji S, Bableshwar A, Bindra MS. Age-related reference
intervals for immunoglobulin levels and lymphocyte subsets in Indian
children. Indian J PatholMicrobiol. 2017;60:360–4.
15. Meites S, Buffone GJ, editors. Pediatric clinical chemistry :
reference (normal) values. 3rd ed. Washington, DC: American Association
for Clinical Chemistry; 1989.
16. O’Connor D, Bate J, Wade R, Clack R, Dhir S, Hough R, et al.
Infection-related mortality in children with acute lymphoblastic
leukemia: an analysis of infectious deaths on UKALL2003. Blood.
2014;124:1056–61.
17. Luczynski W, Stasiak-Barmuta A, Krawczuk-Rybak M. Immunologic
monitoring of maintenance therapy for acute lymphoblastic leukaemia in
children - preliminary report. Pediatr Blood Cancer. 2004;42:416–20.
18. El-Chennawi FA, Al-Tonbary YA, Mossad YM, Ahmed MA. Immune
reconstitution during maintenance therapy in children with acute
lymphoblastic leukemia, relation to co-existing infection. Hematology.
2008;13:203–9.
19. Eyrich M, Wiegering V, Lim A, Schrauder A, Winkler B, Schlegel PG.
Immune function in children under chemotherapy for standard risk acute
lymphoblastic leukaemia - a prospective study of 20 paediatric patients.
Br J Haematol. 2009;147:360–70.
20. Lovat PE, Robinson JH, Windebank KP, Kernahan J, Watson JG. Serial
study of t lymphocytes in childhood leukemia during remission.
PediatrHematolOncol. 1993;10:129–39.
21. Ek T, Mellander L, Hahn-Zoric M, Abrahamsson J. Intensive treatment
for childhood acute lymphoblastic leukemia reduces immune responses to
diphtheria, tetanus, and Haemophilusinfluenzae type b. J
PediatrHematolOncol. 2004;26:727–34.
22. Borzy MS, Ridgway D. Prolonged defects of interleukin-2 production,
responsiveness, and receptor expression in patients with acute
lymphoblastic leukemia. Blood. 1989;73:1608–14.
23. Boldt DH, Von Hoff DD, Kuhn JG, Hersh M. Effects on human peripheral
lymphocytes of in vivo administration of
9-beta-D-arabinofuranosyl-2-fluoroadenine-5’-monophosphate (NSC 312887),
a new purine antimetabolite. Cancer Res. 1984;44:4661–6.
24. Haynes BF, Fauci AS. The differential effect of in vivo
hydrocortisone on the kinetics of subpopulations of human peripheral
blood thymus-derived lymphocytes. J Clin Invest. 1978;61:703–7.
25. Inaba H, Pei D, Wolf J, Howard SC, Hayden RT, Go M, et al.
Infection-related complications during treatment for childhood acute
lymphoblastic leukemia. Ann Oncol. 2017;28:386–92.